☆ 4.8 Article

Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials

CIRCULATION (2022)

Related references

Note: Only part of the references are listed.

Article Urology & Nephrology

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

Peter Rossing et al.

Summary: The FIDELIO-DKD study investigated the treatment effect of finerenone in patients with CKD and T2D, showing that finerenone can improve UACR and have beneficial effects on kidney and cardiovascular outcomes, regardless of whether patients were also using SGLT-2i.

KIDNEY INTERNATIONAL REPORTS (2022)

Add to Collection

Article Transplantation

Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population

James B. Wetmore et al.

Summary: This study found that the risk of RAAS inhibitor interruption and cessation increased with advancing CKD stage. Hyperkalemia was one of the main reasons for interruptions and cessations. Therefore, efforts to prevent hyperkalemia and other factors could decrease treatment interruptions for patients with conditions such as CKD, heart failure, or diabetes.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis

Darren K. McGuire et al.

Summary: SGLT2 inhibitors were found to reduce the risk of major adverse CV events and showed significant heterogeneity in associations with CV death. The most consistent benefit of this class of drugs was a reduction in risk for heart failure and kidney outcomes, with heart failure risk reduction being the most consistent observation across the trials.

JAMA CARDIOLOGY (2021)

Add to Collection

Article Endocrinology & Metabolism

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial

Rosalie A. Scholtes et al.

Summary: Dapagliflozin reduced blood pressure without significant changes in urinary sodium excretion during standardized sodium intake, suggesting factors other than natriuresis and volume changes may contribute to its blood pressure-lowering effects.

DIABETES CARE (2021)

Add to Collection

Letter Endocrinology & Metabolism

Changes in Cardiovascular Biomarkers Associated With the Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes

Patrick R. Lawler et al.

DIABETES CARE (2021)

Add to Collection

Article Urology & Nephrology

Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence

Gregory L. Hundemer et al.

Summary: In older adults with RAASi-related hyperkalemia, discontinuation of RAASi is associated with the lowest risk of recurrent hyperkalemia, with no apparent increase in short-term risks for cardiovascular events or all-cause mortality.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists An Analysis of DAPA-HF

Li Shen et al.

Summary: The study showed that the efficacy and safety of dapagliflozin were similar in patients with HFrEF taking or not taking an MRA, supporting the use of both drugs together.

JACC-HEART FAILURE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure

Joao Pedro Ferreira et al.

Summary: In patients with heart failure and reduced ejection fraction, the effects of empagliflozin were similar in those using or not using MRAs. Empagliflozin treatment was associated with less discontinuation of MRAs.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

Brendon L. Neuen et al.

Summary: The study findings suggest that SGLT2 inhibition with canagliflozin may reduce the risk of hyperkalaemia in patients with type 2 diabetes mellitus and chronic kidney disease treated with renin-angiotensin-aldosterone system inhibitors without increasing the risk of hypokalaemia.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Review Medicine, General & Internal

Chronic kidney disease

Kamyar Kalantar-Zadeh et al.

Summary: Chronic kidney disease is a progressive disease with no cure, and preserving kidney function through lifestyle adjustments and pharmacological interventions can improve outcomes. A plant-dominant, low-protein, and low-salt diet may help mitigate glomerular hyperfiltration and preserve renal function. Various pharmacotherapies can also be used to alter intrarenal haemodynamics and protect the kidney from further damage.

LANCET (2021)

Add to Collection

Article Urology & Nephrology

Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Catherine M. Clase et al.

KIDNEY INTERNATIONAL (2020)

Add to Collection

Article Endocrinology & Metabolism

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

John B. Buse et al.

DIABETES CARE (2020)

Add to Collection

Article Endocrinology & Metabolism

Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020

DIABETES CARE (2020)

Add to Collection

Article Medicine, General & Internal

Estimating lifetime benefits of comprehensive disease -modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials

Muthiah Vaduganathan et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J. L. Heerspink et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

George L. Bakris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Christopher P. Cannon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

V. Perkovic et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Endocrinology & Metabolism

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

Brendan L. Neuen et al.

LANCET DIABETES & ENDOCRINOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

S. D. Wiviott et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Urology & Nephrology

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

William G. Herrington et al.

CLINICAL KIDNEY JOURNAL (2018)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Review Urology & Nephrology

Epidemiology of hyperkalemia: an update

Csaba P. Kovesdy

KIDNEY INTERNATIONAL SUPPLEMENTS (2016)

Add to Collection

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Urology & Nephrology

Regulation of Potassium Homeostasis

Biff F. Palmer

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)

Add to Collection

Article Endocrinology & Metabolism

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

H. J. Lambers Heerspink et al.

DIABETES OBESITY & METABOLISM (2013)

Add to Collection

Article Urology & Nephrology

Mechanisms in Hyperkalemic Renal Tubular Acidosis

Fiona E. Karet

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.